Cisplatin Binding and Cell Survival
Author Information
Author(s): J.E. Melvik, J.M. Dornish, E.O. Pettersen
Primary Institution: Institute for Cancer Research, The Norwegian Radium Hospital
Hypothesis
The binding of cis-dichlorodiammineplatinum(II) to serum proteins and cellular components affects drug uptake and cytotoxicity.
Conclusion
Cisplatin's cytotoxicity is reduced when it binds to serum proteins, and electropermeabilisation can enhance cell survival by increasing drug efflux.
Supporting Evidence
- The cytotoxicity of cis-DDP was lost by binding to serum protein.
- Electropermeabilisation increased cell survival when applied shortly after cis-DDP treatment.
- The binding rate of cis-DDP to biological molecules was quicker intracellularly than extracellularly.
- The biological half-life of cis-DDP was about 2.1 hours in serum and about 11 minutes inside cells.
Takeaway
Cisplatin can be less effective if it sticks to proteins in the blood, but using a special technique can help cells get rid of it and survive better.
Methodology
The study involved treating NHIK 3025 cells with cis-DDP and measuring cell survival and drug binding using electropermeabilisation and atomic absorption spectroscopy.
Limitations
The study primarily focused on a single cell line and may not generalize to other types of cells.
Participant Demographics
Human NHIK 3025 cells derived from uterine cervix carcinoma.
Want to read the original?
Access the complete publication on the publisher's website